CASTLE ROCK, Colo.,
July 1, 2014 /PRNewswire/ -- Venaxis,
Inc. (Nasdaq: APPY), an in vitro diagnostic company focused
on obtaining FDA clearance and commercializing its CE Marked
APPY1™ Test, a rapid, multiple biomarker-based assay for
identifying patients that are at low risk for appendicitis, today
announced it will participate in the third annual ICV Company
Outreach Summit, being held July 9-10,
2014, in Montauk, New York.
Steve Lundy, President and CEO of
Venaxis® will be presenting at the conference to investors
including representatives from hedge and private equity funds as
well as high net worth individuals and family funds.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused
on the clinical development and commercialization of its CE Marked
APPY1 Test, the Company's rapid, protein biomarker-based
assay for appendicitis. This unique appendicitis test has
projected high sensitivity and negative predictive value and is
being developed to aid in the identification of patients at low
risk for acute appendicitis, allowing for more conservative patient
management. The APPY1 Test is being developed
initially for pediatric, adolescent and young adult patients with
abdominal pain, as this population is at the highest risk for
appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being
sought, an initial launch for the APPY1 Test is ongoing in
select European countries. For more information, visit
www.venaxis.com.
Forward-Looking Statements
This press release includes "forward-looking statements" of
Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange
Commission ("SEC"). All statements, other than statements of
historical fact, included in this press release that address
activities, events or developments that Venaxis believes or
anticipates will or may occur in the future are forward-looking
statements. These statements are based on certain assumptions
made based on experience, expected future developments and other
factors Venaxis believes are appropriate in the
circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the
control of Venaxis. Investors are cautioned that any such
statements are not guarantees of future performance. Actual
results or developments may differ materially from those projected
in the forward-looking statements as a result of many factors,
including our ability to obtain FDA clearance or approval, maintain
CE Marking, cost effectively manufacture and generate revenues from
the APPY1 Test at a profitable price point, execute
agreements required to successfully advance the company's
objectives, retain the management team to advance the products,
overcome adverse changes in market conditions and the regulatory
environment, obtain and enforce intellectual property rights, and
realize value of intangible assets. Furthermore, Venaxis does not
intend (and is not obligated) to update publicly any
forward-looking statements. The contents of this press
release should be considered in conjunction with the risk factors
contained in Venaxis' recent filings with the SEC, including its
Form 10-K for the year ended December 31,
2013, filed with the SEC on March 28,
2014.
Venaxis and APPY1 are trademarks of Venaxis, Inc.
Contact – Jed Mahan,
jmahan@venaxis.com; (303) 794-2000 Ext. 255
SOURCE Venaxis, Inc.